144 mTOR pathway assets identified targeting non-oncology indications, expanded from direct mTOR to the full pathway: PI3K/AKT upstream, TSC1/2-Rheb, mTORC1/2, and downstream effectors. 84 preclinical, 36 clinical (Phase I-III), 17 approved.

PI3K/AKT upstream dominates with 60 assets (42%), reflecting the hypothesis that upstream modulation provides superior metabolic control. Direct mTORC1/mTOR inhibitors represent 31 assets. The TSC1/2-Rheb axis shows 21 assets as an emerging node.

67% of clinical assets (24 of 36) remain unpartnered despite Phase II-III maturity. Advanced unpartnered assets offer near-term acquisition opportunities with clinical validation complete and no competitive deal structures to navigate. Four research collaborations provide upgrade potential.

26 of 36 clinical assets (72%) have human evidence, but quality varies by node. mTORC1/mTOR shows a 70% evidence rate, drawing on historical rapalog clinical experience. PI3K/AKT upstream relies on mechanistically indirect measurements.

40 assets in lead selection and 19 in preclinical toxicology indicate near-term IND potential. PI3K/AKT upstream contains 56% of the preclinical pipeline. 25 early-stage assets in discovery and lead optimization signal sustained innovation.